# Contents

1. Introduction and purpose ................................................................. 3
2. Clinical Criteria ............................................................................. 3
3. Contraindications and Precautions .................................................. 3
4. Proposed place in Therapy ............................................................... 3
5. Dosage and Duration of therapy ....................................................... 4
6. Monitoring requirements ................................................................. 6
7. Evaluating effectiveness ................................................................. 6
8. Management of complications ......................................................... 6
9. References .................................................................................... 7
10. Record of amendments to this document ......................................... 7
1. Introduction and purpose
These Guidelines were developed in conjunction with Corneal Research Group at the University of Sydney Save Sight Institute. The aim of the document is to provide guidance to ophthalmologists around the prescribing protocol for the treatment of Herpes Simplex Keratitis.

2. Clinical Criteria
Herpes Simplex Keratitis is a clinical condition and diagnosis is based on the following clinical criteria:

- Epithelial keratitis (dendritic ulcer)
- Stromal keratitis: vascularisation, scarring, lipid keratopathy, ulceration
- Endothelial keratitis: Stromal oedema and keratic precipitates
- Keratouveitis: Corneal epithelial and/or stromal edema, stromal keratitis, keratic precipitates, and anterior chamber cells

Investigations required include Herpes simplex virus (HSV) PCR.

3. Contraindications and Precautions
Identified allergy to aciclovir and valaciclovir is a contra-indication. Precautions to note when prescribing include:

- Renal
- Increased risk of neurological adverse effects in renal impairment
- Dose adjustment is required

Pregnancy
- Valaciclovir is metabolised rapidly to aciclovir; limited data do not suggest an increased risk of congenital malformations, however, aciclovir is preferred as there is more clinical experience valaciclovir may be used from 36 weeks of pregnancy

Breastfeeding
- Safe to use

4. Proposed place in Therapy
Medical practitioners are required to state whether the drug is be used as first, second or third line. Aciclovir or valaciclovir are used as first line therapy for herpes simplex keratitis.
## 5. Dosage and Duration of therapy

It is recommended that the Ophthalmologist adjust dosage for specific patient groups.

<table>
<thead>
<tr>
<th></th>
<th>Local Treatment Dosage</th>
<th>Systemic Treatment Dosage</th>
</tr>
</thead>
</table>
| Epithelial HSK       | **Topical aciclovir 5 times a day for 1-2 weeks** | Immunocompromised patients Non-compliance, inability to use or tolerate, or ocular toxicity from topical aciclovir  
**Oral Valaciclovir 500 mg BD for 7 days** |
|                      | Without epithelial ulcer                     | With epithelial ulcer:  
**ORAL Valaciclovir 500 mg ONCE a day during topical steroid use PLUS  
Prednefrin Forte eye drops 4-6 times a day tapered over > 10 weeks**  
**Oral Valaciclovir 1 g TDS for 7-10 days**  
PLUS  
Prednefrin Forte eye drops BD tapered slowly as disease comes under control |
| Stromal HSK          | **ORAL Valaciclovir 500 mg to 1 g ONCE a day to TDS for 7-10 days**  
PLUS  
Prednefrin Forte eye drops 4-6 times a day tapered over > 10 weeks  
**Oral Valaciclovir 1 g TDS for 7-10 days**  
PLUS  
Prednefrin Forte eye drops BD tapered slowly as disease comes under control |
| Endothelial HSK      | **ORAL Valaciclovir 500 mg to 1 g ONCE a day to TDS for 7-10 days**  
PLUS  
Prednefrin Forte eye drops 4-6 times a day tapered over > 10 weeks  
**Oral Valaciclovir 1 g TDS for 7-10 days**  
PLUS  
Prednefrin Forte eye drops BD tapered slowly as disease comes under control |
| Keratouveitis        | **ORAL Valaciclovir 1 g TDS for 7-10 days**  
PLUS  
Prednefrin Forte eye drops 4-6 times a day tapered over > 10 weeks  
Refer patient to cornea/uveitis clinic, respectively depending on degree of cornea or uveal involvement |

### Prophylaxis

**Indications:**
- Multiple recurrences of any type of HSK, especially stromal HSK
- Patients with a history of ocular HSV:
  - following any ocular surgery, including penetrating keratoplasty
  - during immunosuppressive treatment
- **Oral Aciclovir 400 mg BD**
- OR  
  **Oral Valaciclovir 500 mg ONCE a day**

* Reduce Valaciclovir to prophylactic dose after 7-10 days and maintain for as long as frequent topical steroids are in use
† There is a lack of clinical evidence to guide dosage in this situation

### Adult Renal Dosing for oral antivirals

<table>
<thead>
<tr>
<th>CrCl(mL/min)</th>
<th>Dose</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal dosage Valaciclovir 500 mg ONCE a day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>500 mg</td>
<td>Every 48 hours</td>
</tr>
<tr>
<td>Normal dosage Valaciclovir 500 mg BD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>500 mg</td>
<td>Every 24 hours</td>
</tr>
<tr>
<td>Normal dosage Valaciclovir 1 g TDS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-49</td>
<td>1 g</td>
<td>Every 12 hours</td>
</tr>
<tr>
<td>10-29</td>
<td>1 g</td>
<td>Every 24 hours</td>
</tr>
<tr>
<td>&lt;10</td>
<td>500 mg</td>
<td>Every 24 hours</td>
</tr>
<tr>
<td>Normal dosage Aciclovir 400mg BD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-10</td>
<td>200 mg</td>
<td>Every 12 hours</td>
</tr>
</tbody>
</table>

### Use in Pregnancy

- **Aciclovir**  
  Preferred due to more clinical experience. Category B3
- **Valaciclovir**  
  Limited data do not suggest increased risk of congenital malformations. May be used from 36 weeks of pregnancy. Category B3.
Paediatric Dosing

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aciclovir</td>
<td>Drug of choice</td>
</tr>
<tr>
<td>Valaciclovir</td>
<td>Must only be used in children &gt;12 years old</td>
</tr>
</tbody>
</table>

Local treatment

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months to 18 years</td>
<td>Epithelial HSK: Topical aciclovir 5 times a day for 14 days or for at least 3 days after healing, whichever is shorter</td>
</tr>
</tbody>
</table>

Systemic treatment dosage

Indications:
- Stromal HSK
- Skin involvement
- Coexistent systemic disease
- Non-compliance, inability to use or tolerate, or ocular toxicity from topical aciclovir
- Immunocompromised patients – seek advice from a Paediatric Infection Diseases Physician

Birth (at term) to 3 months
Seek advice from Paediatric Infection Diseases Physician

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months to 12 years</td>
<td>Oral aciclovir 10 mg/kg (max 400 mg) 5 times a day for 5-7 days or until there are no new lesions PLUS Prednefrin Forte eye drops BD-QID a day. (For severe inflammation, consider hourly dosing for 1-2 days)</td>
</tr>
<tr>
<td>12 years to 18 years</td>
<td>Oral aciclovir 10 mg/kg (max 400 mg) 5 times a day for 5-7 days or until there are no new lesions OR Oral Valaciclovir 500 mg BD for 5 days if first episode (longer if new lesions appear during treatment or healing is incomplete) OR Oral Valaciclovir 500 mg BD for 3-5 days if recurrent episode PLUS Prednefrin Forte eye drops BD-QID a day. (For severe inflammation, consider hourly dosing for 1-2 days)</td>
</tr>
</tbody>
</table>

Important Drug Interactions

- **Mycophenolate**
  Mycophenolate may increase aciclovir/valaciclovir concentration; renal excretion of both drugs may be reduced in renal impairment, may increase risk of adverse effects, e.g. neutropenia; dosage adjustment not usually necessary.

- **Theophylline**
  Aciclovir/valaciclovir may increase theophylline concentration and risk of adverse effects; monitor theophylline concentration and for adverse effects; decrease theophylline dose as needed.
Administration Instructions:

- With systemic treatment, ensure adequate hydration (especially if receiving high doses) to minimise renal adverse effects
- Patient to be advised to take tablets with a full glass of water
- Need to ensure patients have the correct technique for administration for eye drops / ointment

6. Monitoring requirements

- Patient needs to be reviewed by ophthalmologist once the therapy has started according to the guidelines. Monitoring requirements to ascertain safety of use include:
  - **Blood and lymphatic system disorders**: Very rare: anaemia, leukopenia, thrombocytopenia.
  - **Immune system disorders**: Rare: anaphylaxis.
  - **Psychiatric and nervous system disorders**: Common: headache, dizziness, confusion, hallucinations, somnolence, convulsions. Very rare: agitation, tremor, ataxia, dysarthria, psychotic symptoms, encephalopathy, coma. The above events are reversible and usually reported in patients with renal impairment in whom the dosage was in excess of that recommended, or with other predisposing factors.
  - **Respiratory, thoracic and mediastinal disorders**: Rare: dyspnoea.
  - **Gastrointestinal disorders**: Common: nausea, vomiting, diarrhoea, abdominal pains.
  - **Hepatobiliary disorders**: Rare: reversible rises in bilirubin and liver related enzymes. Very rare: hepatitis, jaundice.
  - **Skin and subcutaneous tissue disorders**: Common: pruritus, rashes (including photosensitivity). Uncommon: urticaria, accelerated diffuse hair loss. Rare: angioedema.
  - **Renal and urinary disorders**: Rare: increases in blood urea and creatinine. Very rare: acute renal failure, renal pain. Renal pain may be associated with renal failure.
  - **General disorders**: Common: fatigue, fever.

7. Evaluating effectiveness

Drug treatment effectiveness is indicated by improvement of vision acuity and of clinical signs including:

- Resolution of epithelial defect or punctate corneal staining
- Reduction in inflammation of cornea stromal or anterior chamber
- Resolution stromal infiltrates

8. Management of complications

If complications such as changes in renal function during systemic treatment occur, best practice involves the following approaches:

- Rehydration
- Dosage reduction
- Stopping the drug

9. References

6. Australian Medical Handbook Children’s Dosing Companion
7. British National Formulary for children

10. Record of amendments to this document

<table>
<thead>
<tr>
<th>Page</th>
<th>Details of Amendment</th>
<th>Date amended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Entire document</td>
<td>Created</td>
<td>February 2020</td>
</tr>
</tbody>
</table>